Aidoc
Clinical AI platform for radiology and enterprise imaging workflows.
Last updated: June 5, 2026
Back to directoryCE Class IIb autonomous chest X-ray AI workflow positioned to identify normal studies and generate reports without radiologist review in selected markets.
European radiology programs studying tightly governed autonomous normal-study reporting after retrospective and supervised validation.
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Oxipit ChestLink as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat ChestLink as a high-risk autonomous radiology workflow and verify the exact CE Class IIb certificate, intended use, country availability, version, and absence or presence of FDA authorization before any clinical deployment. |
|---|---|
| Privacy | Review DICOM image routing, patient identifiers, RIS/PACS integration, analytics dashboards, support access, retention, security controls, and the customer data-processing agreement rather than relying on the public website privacy notice. |
| Evidence | Require local retrospective validation and supervised operation data before autonomous release, with special attention to false negatives, abnormality prevalence, scanner mix, excluded cases, and monitoring sensitivity. |
| Workflow | Best governed as a staged autonomous-normal-CXR program with explicit release thresholds, radiologist oversight for all uncertain or abnormal cases, audit review, downtime fallback, and safety-event escalation. |
Oxipit describes ChestLink as a CE Class IIb autonomous AI imaging application for chest X-ray analysis that reports high-confidence studies with no abnormalities; Oxipit materials outline retrospective, supervised, and autonomous deployment phases, while Sectra announced and completed its acquisition of Oxipit in 2026. Oxipit's privacy notice is a website notice, so clinical data-processing terms should be checked contractually.
Not for: U.S. clinical use without FDA authorization, abnormal-study reporting, unsupported modalities, emergency workups without escalation, or replacing local radiologist accountability outside the certified workflow.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.